Identification of Adropin as a Secreted Factor Linking Dietary Macronutrient Intake with Energy Homeostasis and Lipid Metabolism by Kumar, K. Ganesh et al.
Louisiana State University 
LSU Digital Commons 
Faculty Publications Department of Biological Sciences 
12-6-2008 
Identification of Adropin as a Secreted Factor Linking Dietary 
Macronutrient Intake with Energy Homeostasis and Lipid 
Metabolism 
K. Ganesh Kumar 
Pennington Biomedical Research Center 
James L. Trevaskis 
Pennington Biomedical Research Center 
Daniel D. Lam 
University of Cambridge 
Gregory M. Sutton 
Pennington Biomedical Research Center 
Robert A. Koza 
Pennington Biomedical Research Center 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.lsu.edu/biosci_pubs 
Recommended Citation 
Kumar, K., Trevaskis, J., Lam, D., Sutton, G., Koza, R., Chouljenko, V., Kousoulas, K., Rogers, P., Kesterson, 
R., Thearle, M., Ferrante, A., Mynatt, R., Burris, T., Dong, J., Halem, H., Culler, M., Heisler, L., Stephens, J., & 
Butler, A. (2008). Identification of Adropin as a Secreted Factor Linking Dietary Macronutrient Intake with 
Energy Homeostasis and Lipid Metabolism. Cell Metabolism, 8 (6), 468-481. https://doi.org/10.1016/
j.cmet.2008.10.011 
This Article is brought to you for free and open access by the Department of Biological Sciences at LSU Digital 
Commons. It has been accepted for inclusion in Faculty Publications by an authorized administrator of LSU Digital 
Commons. For more information, please contact ir@lsu.edu. 
Authors 
K. Ganesh Kumar, James L. Trevaskis, Daniel D. Lam, Gregory M. Sutton, Robert A. Koza, Vladimir N. 
Chouljenko, Konstantin G. Kousoulas, Pamela M. Rogers, Robert A. Kesterson, Marie Thearle, Anthony W. 
Ferrante, Randall L. Mynatt, Thomas P. Burris, Jesse Z. Dong, Heather A. Halem, Michael D. Culler, Lora K. 
Heisler, Jacqueline M. Stephens, and Andrew A. Butler 
This article is available at LSU Digital Commons: https://digitalcommons.lsu.edu/biosci_pubs/3295 
Cell Metabolism
Article
Identification of Adropin as a Secreted Factor
Linking Dietary Macronutrient Intake with Energy
Homeostasis and Lipid Metabolism
K. Ganesh Kumar,1,11 James L. Trevaskis,1,11 Daniel D. Lam,2 Gregory M. Sutton,1 Robert A. Koza,3
Vladimir N. Chouljenko,4 Konstantin G. Kousoulas,4 Pamela M. Rogers,5 Robert A. Kesterson,6 Marie Thearle,7
Anthony W. Ferrante, Jr.,7 Randall L. Mynatt,8 Thomas P. Burris,5 Jesse Z. Dong,9 Heather A. Halem,9 Michael D. Culler,9
Lora K. Heisler,2 Jacqueline M. Stephens,10 and Andrew A. Butler1,8,*
1Neuropeptides Laboratory, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA
2Department of Pharmacology, University of Cambridge, Cambridge CB2 1PD, UK
3Genomics Core Facility, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA
4Division of Biotechnology and Molecular Medicine, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70802, USA
5Nuclear Receptor Biology Laboratory, Pennington Biomedical Research Center, Louisiana State University System,
Baton Rouge, LA 70808, USA
6Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
7Naomi Berrie Diabetes Center, Columbia University Medical Center, New York, NY 10032, USA
8Clinical Nutrition Research Unit, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA
9Biomeasure Incorporated, IPSEN, Milford, MA 01757, USA
10Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70802, USA




Obesity and nutrient homeostasis are linked by
mechanisms that are not fully elucidated. Here we
describe a secreted protein, adropin, encoded by
a gene, Energy Homeostasis Associated (Enho),
expressed in liver and brain. Liver Enho expression
is regulated by nutrition: lean C57BL/6J mice fed
high-fat diet (HFD) exhibited a rapid increase, while
fasting reduced expression compared to controls.
However, liver Enho expression declines with diet-
induced obesity (DIO) associated with 3 months of
HFD or with genetically induced obesity, suggesting
an association with metabolic disorders in the obese
state. In DIO mice, transgenic overexpression or sys-
temic adropin treatment attenuated hepatosteatosis
and insulin resistance independently of effects on
adiposity or food intake. Adropin regulated expres-
sion of hepatic lipogenic genes and adipose tissue
peroxisome proliferator-activated receptor gamma,
a major regulator of lipogenesis. Adropin may there-
fore be a factor governing glucose and lipid homeo-
stasis, which protects against hepatosteatosis and
hyperinsulinemia associated with obesity.
INTRODUCTION
The obesity ‘‘epidemic’’ has been associated with increased
prevalence of metabolic diseases associated with excess adi-
posity (Cowie et al., 2006; Perlemuter et al., 2007). Obesity re-
sults from a failure to adapt to abundant calories and reduced
physical activity (Hill, 2006). Obesity is frequently associated
with insulin resistance, which proceeds to type 2 diabetes
when pancreatic b cells cannot compensate by increasing insu-
lin production (Biddinger and Kahn, 2006). Several mechanisms
linking obesity with insulin resistance have been proposed, in-
cluding inflammation and impaired function of hypothalamic
centers involved in energy homeostasis (Flier, 2004; Hotamisligil,
2006; Morino et al., 2006). An association between disorders of
lipid metabolism and insulin resistance is also evident. Excess
energy is normally stored in the triacylglycerol (TG) pool in white
adipose tissue (WAT). However, the ectopic accumulation of
fatty acids (steatosis) in liver, skeletal muscle, and the pancreas
has been linked to insulin resistance and type 2 diabetes (Morino
et al., 2006). While steatosis could be a factor causing insulin re-
sistance, hyperinsulinism exacerbates steatosis by further stim-
ulating lipogenesis (Morino et al., 2006; Perlemuter et al., 2007;
Petersen et al., 2007).
Peptides secreted from peripheral organs regulate lipid me-
tabolism in key insulin-target tissues and are important for en-
ergy homeostasis and maintaining insulin sensitivity (Reitman,
2007; Scherer, 2006; Sharma and Staels, 2007). Much attention
has been given to adipokines secreted by adipocytes. Adipo-
kines act as paracrine factors within WAT, and as endocrine hor-
mones acting on the liver, muscles, and central nervous system
(CNS) to regulate energy homeostasis (Scherer, 2006). For ex-
ample, adiponectin promotes insulin sensitivity and stimulates
fat oxidation in liver and muscle (Scherer, 2006; Sharma and
Staels, 2007) while promoting the storage of TG preferentially
in WAT (Kim et al., 2007). Leptin acts on hypothalamic neurons
that act as relays to sites regulating ingestive behavior, periph-
eral lipid metabolism, and insulin sensitivity (Morton et al.,
2006). Reduced function of adiponectin and leptin contribute
to insulin resistance associated with obesity. However, obesity
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is also associated with secretion of factors from WAT promoting
insulin resistance, including resistin and proinflammatory cyto-
kines (Scherer, 2006; Sharma and Staels, 2007).
While receiving less attention, liver-secreted factors are also
critical for energy homeostasis (Reitman, 2007). These act as
paracrine and endocrine factors that regulate carbohydrate,
lipid, and amino acid metabolism during periods of altered nutri-
tional status (Reitman, 2007; LeRoith and Yakar, 2007). Here we
describe a novel secreted peptide initially identified during mi-
croarray analysis of liver gene expression in mouse models of
obesity. Adropin (derived from the Latin roots ‘‘aduro’’ [to set
fire to] and ‘‘pinquis’’ [fats or oils]) is encoded by the Energy
Homeostasis Associated gene (gene symbol: Enho). Liver Enho
expression is regulated by energy status and dietary nutrient
content, and is altered with obesity. Transgenic overexpression
or systemic adropin treatment improves diet-induced obesity
(DIO), insulin resistance, and glucose tolerance. Adropin also at-
tenuates components of the metabolic distress associated with
obesity independently of effects on body weight or weight loss.
Collectively, our data suggest that adropin is a secreted factor in-
volved in energy homeostasis that could provide a promising
new lead for developing therapies against the metabolic disor-
ders associated with obesity.
RESULTS
Hypothalamic obesity is associated with insulin resistance and
hepatic steatosis (Sutton et al., 2006). To further investigate hy-
pothalamic regulation of liver metabolism, we performed a global
analysis of gene expression in C57BL/6J (B6) melanocortin-3
receptor-deficient (Mc3r/) mice. During validation of microar-
ray data, we identified an unknown liver transcript downregu-
lated with obesity. RIKEN cDNA 2310040A07 encodes a short
(<1 kb) mRNA, encoding a highly conserved 76 aa open reading
frame (ORF) (Figures 1A and 1B). Bioinformatics analysis using
SignalP 3.0 (Emanuelsson et al., 2007) suggested that the pep-
tide is likely (87% probability) to be secreted, with the most prob-
able cleavage site between residues 33 and 34. Secretion of
peptide was confirmed in HEK293 cells and mice by using car-
boxy-terminal FLAG-tagged expression vectors. FLAG immuno-
reactivity (IR) was observed in conditioned media of HEK293
cells transfected with pCMV-Enho:FLAG (Figure 1C). FLAG-IR
was also observed in sera from B6 mice injected with 108–109
plaque-forming units (pfu) of recombinant adenovirus that ex-
presses the FLAG-labeled adropin into the tail vein (Figure 1D).
Analysis of tissue distribution by northern blot revealed a tran-
script of 1.3 kB abundant in liver and whole brain of mice and
humans (Figure 1E). As nothing was known about expression
of the transcript in the brain, we further analyzed its distribution
in the mouse by in situ hybridization histochemistry using three
separate riboprobes. Dense Enho expression was observed in
areas of the thalamus, midbrain, and hindbrain (Figure 1F). Abun-
dant Enho mRNA was observed in the medial habenula, the dor-
sal premamillary nucleus of the hypothalamus, the medial septal
complex (medial septum and the nucleus of the diagonal band),
and the thalamus (the posterior thalamic nuclear group, the
lateral and medial geniculate nuclei, and the paraventricular,
anterodorsal, ventral posterolateral, and ventral posteromedial
thalamic nuclei). In the midbrain, high levels of Enho mRNA
were evident in the substantia nigra pars compacta, interpe-
duncular nucleus, red nucleus, periaqueductal gray, and me-
dian raphe. Enho mRNA was observed in the pontine nuclei
and the reticulotegmental nucleus of the pons. Dense Enho
mRNA was also identified in regions of the medulla, including
the medial vestibular nucleus, prepositus nucleus, facial nu-
cleus, inferior olive, lateral reticular nucleus, dorsal vagal com-
plex, area postrema, and cuneate nucleus. Sense probes pro-
duced no detectable hybridization (data not shown). Together,
these observations suggest that the transcript is abundant in
areas involved in the control of complex behaviors, including
circadian rhythms and stress response, and in areas that reg-
ulate peripheral metabolism through the autonomic nervous
system.
Regulation of Liver Enho Expression
As the transcript was initially identified by exhibiting reduced ex-
pression in liver of Mc3r/ mice, its expression in lean and
obese states was further investigated by northern and quantita-
tive RT-PCR. Obesity due to deficiency in melanocortin receptor
signaling (lethal yellow Ay/a, Mc3r/, and Mc4r/) or leptin
(Lepob/Lepob) is associated with marked reductions in liver
Enho mRNA compared to lean wild-type (WT) controls (Figures
1E and 2A). We next determined whether altered Enho expres-
sion is related to obesity or is a specific consequence of disrup-
ted melanocortin signaling. Prevention of obesity in Ay/a mice by
calorie restriction (CR) (body weight [BW] in g, 20.7 ± 1.4 g)
normalized liver Enho mRNA compared to obese ad libitum-
fed Ay/a mice (BW of 48.2 ± 1.4 g) (Figure 2B). Reduced hepatic
Enho mRNA in Ay/a mice is thus a secondary effect of obesity.
To investigate whether nutritional status affects liver Enho
mRNA, we examined regulating by fasting and short- to long-
term exposure to high-fat diet (HFD: 60% kJ from fat, 20% kJ/
carbohydrate, 20% kJ/protein). DIO in B6 mice induced by
3 months of HFD was associated with reduced liver Enho
mRNA compared to lean controls (expression as a ratio of con-
trol: 1.00 ± 0.18 versus 0.53 ± 0.19, n = 4 for DIO, n = 5 for control,
p = 0.06). However, while chronic exposure to DIO reduced ex-
pression, the results from studies investigating acute regulation
by diet showed a dynamic response. A 9-fold increase in liver
Enho mRNA was observed in mice fed HFD for 2 days compared
to mice fed low-fat diet (LFD: 10% kJ from fat, 70% kJ/carbohy-
drate, 20% kJ/protein) (Figure 2C). Further analysis of expres-
sion in mice subject to 2 days, 7 days, 14 days, or 28 days of
either HFD or LFD (n = 3–4 per group) showed a complex
biphasic pattern of regulation, with significantly increased
expression in the HFD-fed relative to LFD-fed mice on day 2 or
day 28 (Figure 2D). The decline in liver Enho mRNA with DIO is
thus presumed to occur after a prolonged (>1 month) exposure
to HFD and may represent malfunction of normal regulation by
macronutrients in the obese state.
Liver Enho mRNA in lean B6 mice was also regulated by fast-
ing, which reduced expression 80% relative to chow-fed animals
(Figure 2E). Consistent with results shown in Figures 2C and 2D,
demonstrating stimulation by HFD, the rebound in expression
during refeeding was affected by macronutrient content of the
diet. Mice refed with LFD exhibited a delayed response relative
to mice refed with HFD (Figure 2E).
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Figure 1. Enho mRNA Encodes a Highly Conserved Secreted Peptide
(A) Enho mRNA sequence with the conserved ORF underlined.
(B) Conservation of adropin sequence in mammals.
(C) Presence of FLAG-IR in cell lysate (L) and conditioned media (M) of HEK293 cells transfected with vectors expressing adropin with or without a C-terminal
FLAG.
(D) Western blot of FLAG-IR in sera collected from B6 mice 1–21 days after injection with 108 pfu of adenovirus expressing FLAG-tagged adropin.
(E) Northern blots showing distribution of Enho mRNA in human (upper panel) and mouse tissues (lower panel). Tissues were obtained from lean B6 (L) or obese
leptin-deficient (O) mice.
(F) A series of autoradiographs summarizing Enho mRNA expression sites across the B6 mouse brain: 7N, facial nucleus; AP, area postrema; Cu, cuneate nu-
cleus; DVC, dorsal vagal complex; HDB, nucleus of the horizontal limb of the diagonal band; LGN, lateral geniculate nucleus; MHb, medial habenula;
MnR, median raphe; MS, medial septum; MVe, medial vestibular nucleus; PAG, periaqueductal gray; PMD, dorsal premamillary nucleus; Pn, pontine nuclei;
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Together, these data indicate that hepatic Enho expression is
influenced by fasting and the macronutrient composition of the
diet, with high expression levels observed during short-term in-
take of diets high in fat content. However, chronic exposure to
HFD is associated with reduced expression, perhaps indicating
deregulation of liver Enho expression with obesity.
The rapid regulation of liver Enho mRNA by macronutrient con-
tent suggested an involvement of intracellular lipid sensors. Per-
oxisome proliferator activated receptor alpha (Ppara) is activated
during the metabolic adaptation to fasting (Reitman, 2007) and
therefore appeared an unlikely candidate for stimulating Enho
expression. The liver X receptors (LXRa and LXRb, also known
as Nr1h2 and Nr1h3) and farnesoid X receptor (FXR, also known
as Nr1h4) are nuclear receptors that are regulated by sterols and
bile acids and are involved in carbohydrate and lipid homeosta-
sis (Kalaany and Mangelsdorf, 2006). Treatment of HepG2 cells
with the LXR agonists GW3965 and TO9 increased expression
of LXRa mRNA (Figure 2F). This is the primary LXR isoform in
HepG2 cells, and its expression is stimulated by LXR agonists
(Laffitte et al., 2003). In these cells, presence of the LXR agonist
reduced Enho expression (Figure 2F), a response blocked by an
antisense RNA targeting LXRa (Figure 2G) and previously shown
to reduce LXRa mRNA and protein (Stayrook et al., 2008). To de-
termine whether activation of LXRa would regulate Enho mRNA
in mouse liver, GW3965 (10 mg/kg) was administered intrave-
nously to lean, chow-fed, male B6 mice. Mice treated with
GW3965 exhibited a significant reduction in liver Enho mRNA
4 hr after injection (Figure 2H). Treatment of HepG2 cells with
the FXR agonist GW4064 significantly increased the expression
of Shp1, as previously reported (Goodwin et al., 2000), but did
not affect Enho expression (Figure 2I).
Together, these results indicate that liver Enho mRNA expres-
sion is regulated by LXRa, a nuclear receptor involved in choles-
terol and triglyceride metabolism (Kalaany and Mangelsdorf,
2006). While we predicted that lipid sensors would stimulate
Enho expression, the opposite effect was observed. The link be-
tween the response observed with activation of LXRa and the
stimulation of hepatic Enho expression by high fat intake thus
remains unclear. However, the rapid regulation by LXRa agonists
observed in cultured cells and in whole animals is further




Thus far, the data obtained from the analysis of expression in
whole animals and HepG2 cells suggested that the Enho gene
is associated with carbohydrate and lipid metabolism, and that
severe obesity is associated with loss of normal regulation. To fur-
ther investigate the association of altered Enho expression with
energy status, we generated transgenic B6 mice overexpressing
adropin (Adr-Tg) (Figure 3A). Widespread expression of the trans-
gene was confirmed by RT-PCR using transgene-selective
primers (Figure 3B) and quantifying expression using primers
simultaneously detecting the endogenous and transgene cDNA
(Figure 3C). Polyclonal antibodies raised against the C terminus
of the putative secreted domain revealed increased adropin IR
in tissue lysates where endogenous protein was detected
(Figure 3D). Adr-Tg mice appear grossly normal, with no evidence
of significant increases in mortality associated with the transgene.
To investigate how the adropin transgene would affect metab-
olism in situations of obesity, we challenged Adr-Tg and wild-
type B6 mice to HFD (60% kJ/fat). At 8 weeks of age, chow-
fed Adr-Tg had normal BW; however, examination of Adr-Tg
mice and WT controls fed HFD from 8 to 14 weeks of age sug-
gested protection from DIO (Figure 3E). Males (Adr-Tg, n = 3;
WT, n = 4) and females (Adr-Tg, n = 7; WT, n = 8) were fed an
HFD for 6 weeks. As predicted, weight gain was significantly
greater in males compared to females (least square means
[LSM] for BW gain in g for males, 12.2 ± 1.0; for females, 5.2 ±
0.7; p < 0.01). Weight gain was significantly attenuated in Adr-
Tg mice (LSM for BW gain in g: for WT, 10.4 ± 0.8; for Adr-Tg,
7.0 ± 0.9; effect of genotype, p = 0.01), due exclusively to reduced
fat mass (FM) (Figure 3F). Similar results were observed in a sec-
ond group of male mice fed HFD for 6 weeks (BW gain in g for WT,
13.2 ± 1.8; for Adr-Tg, 6.8 ± 1.5; p < 0.05; FM gain for WT, 12.3 ±
1.7; for Adr-Tg, 5.6 ± 2.0; p < 0.05; FFM gain for WT, 1.5 ± 0.4; for
Adr-Tg, 1.5 ± 0.8, p = 0.78, N = 3 for Adr-Tg, N = 7 for WT). For this
group, we investigated the effects of a longer duration of HFD.
These results suggested that while DIO in Adr-Tg mice is delayed,
it is not prevented. BW parameters of WT and Adr-Tg converged
after 3 months on HFD (data not shown).
To investigate whether reduced weight gain would improve
the metabolic distress associated with obesity, glucose homeo-
stasis was assessed in Adr-Tg mice with reduced FM (Figures 3E
and 3F). To determine whether adropin affects glucose homeo-
stasis independently of BW, we also examined Adr-Tg mice
matched with controls for BW and adiposity. Glucose homeosta-
sis examined in mice fed HFD for 6 weeks indicated improve-
ments consistent with reduced obesity (Figure 3G). Under fasting
conditions, serum insulin levels were lower in Adr-Tg mice (LSM
in ng/ml: WT 2.7 ± 0.5, Adr-Tg 1.3 ± 0.5, p = 0.05); blood glucose
was not significantly different (LSM in mg/dL: Adr-Tg 189 ± 11;
WT 185 ± 10, p = 0.77). Female Adr-Tg mice exhibited an in-
crease in total serum adiponectin, while serum TG was also re-
duced in Adr-Tg (Figure 3G). These observations suggested
that reduced adiposity due to the overexpression of adropin is
also associated with improvement in glucose homeostasis.
However, these studies did not determine whether adropin af-
fects carbohydrate and lipid metabolism independently of re-
ducing weight.
Secreted factors that regulate energy homeostasis can also
affect glucose homeostasis independently of reducing food
intake or causing weight loss (Asilmaz et al., 2004; Obici et al.,
2001; Zhou et al., 2007). We therefore assessed glucose
homeostasis in male 6- to 7-month-old Adr-Tg and WT mice
(n = 7–8/group) fed standard rodent chow or HFD for 3 months,
which were matched for BW and adiposity (Figure 3H). Adr-Tg
mice again exhibited improved glucose homeostasis, indicated
by reduced fasting insulin, protection from HFD-induced
Po, posterior thalamic nuclear group; Pr, prepositus nucleus; PVP, paraventricular thalamic nucleus; RN, red nucleus; RtTg, reticulotegmental nucleus of the
pons; SNC, substantia nigra pars compacta; Sp5, spinal trigeminal nucleus; TgN, tegmental nucleus; VDB, nucleus of the vertical limb of the diagonal band;
VP, ventral posterolateral thalamic nucleus.
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hyperglycemia, lower homeostasis model assessment of insulin
resistance (HOMA-IR) values (Figure 3I), and significantly en-
hanced glucose clearance in Adr-Tg mice (Figure 3J). Improved
glucose tolerance was also observed in Adr-Tg mice fed chow
(Figure 3J). Significantly, the improvements in glucose homeo-
stasis of the HFD-fed group were not due to significant differ-
ences in energy expenditure (VO2 in ml/gBW/hr for WT: 2296 ±
38; Adr-Tg: 2337 ± 55; p = 0.55), substrate metabolism as indi-
cated by the respiratory quotient (RQ) (WT: 0.765 ± 0.003; Adr-
Tg: 0.764 ± 0.003; p = 0.88), or physical activity (X-movements
Figure 2. Regulation of Liver Enho by Obesity and Nutrition
(A) Liver Enho expression in 6-month-old male Mc3r/, Mc4r/, and Lepob/Lepob mice compared to lean controls. The Mc3r/ and Mc4r/mice used for this
analysis were backcrossed >10 generations onto the B6 background. * p < 0.05 compared to WT, n = 5–6 per group.
(B) Liver Enho mRNA is also reduced in Ay/a mice compared to lean B6 controls, which develop obesity due to hyperphagia associated with expression of an Mc4r
antagonist. The reduced expression of Enho in liver is not observed in Ay/a mice subject to calorie restriction (CR), suggesting that the decline is secondary to
obesity and not a specific defect due to reduced melanocortin receptor signaling (n = 4 per group). * p < 0.05 versus obese Ay/a mice and lean controls.
(C) Feeding lean male B6 mice HFD (60% kJ/fat) for 2 days is associated with increase liver Enho expression compared to mice fed LFD (10% kJ/fat) * p < 0.01.
(D) Differential effects of purified LFD or HFD on the expression of liver Enho mRNA in male B6 mice after 2, 7, 14, or 28 days. * p < 0.05 compared to LFD within
time point (n = 4 per group).
(E) Fasting is associated with reduced liver Enho expression compared to controls that had been fed a purified LFD (10% kJ/fat) for 10 days. The rebound in
expression is affected by dietary fat content, with mice refed LFD (open bars) exhibiting a delayed response compared to mice refed with HFD (black bars)
(n = 5–6 per group). * p < 0.05, ns, no significant difference. Note that the mice used for the studies shown in (C) and (D) were 3 months old, and had been weaned
onto standard rodent chow.
(F) Reduced Enho mRNA in HepG2 cells after 48 hr treatment with LXR agonists (GW3965 [GW]; TO9 [TO]; both 1 mM for 24 hr).
(G) An siRNA targeting LXRa increases Enho mRNA in HepG2 cells treated with GW-3965.
(H) Liver Enho mRNA in 12-week-old B6 mice is significantly reduced 4 hr after intravenous injection with 10 mg/kg GW3965 (n = 4, *p < 0.05).
(I) The FXR agonist GW-4064 (1 mM for 24 hr) increased expression of Shp1 but did not effect Enho expression in HepG2 cells. Values shown in each panel are
mean ± SEM.
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in beam breaks/hr for WT: 417 ± 28; Adr-Tg: 397 ± 20, p = 0.55).
Together, these results strongly suggest that adropin regulation
of glucose homeostasis is independent of changes in BW, food
intake, and whole body energy expenditure.
Delayed DIO in Adr-Tg Mice Is Due to Altered
Metabolism
To investigate how the transgene delays DIO, chow-fed male
and female Adr-Tg and WT controls (n = 7–8, age 8–10 weeks)
were housed in metabolic chambers measuring energy expendi-
ture, whole body substrate oxidation indicated by the RQ, and
physical activity. Adr-Tg and WT mice had similar BW (male
Adr-Tg: 25.1 ± 0.7 g, male WT: 26.4 ± 0.6 g, p = 0.18; female
Adr-Tg: 20.4 ± 0.3 g, female WT: 20.8 ± 0.4 g, p = 0.45). Gen-
der-specific effects of the transgene were observed on energy
metabolism. Resting energy expenditure (REE) and total energy
expenditure (TEE) expressed per mouse were not significantly
different in Adr-Tg and WT mice of either sex (Figure 4A)
(REE in kJ/day for male WT: 26.6 ± 0.7, male Adr-Tg, 27.2 ±
0.8, p = 0.55; for female WT: 17.7 ± 0.5, female Adr-Tg: 17.0 ±
0.2, p = 0.22). However, TEE expressed either per gram of BW
or fat-free mass (FFM) was modestly but significantly increased
in male Adr-Tg mice compared to controls (+3.7 kJ/kgBW/hr,
p < 0.05, Figure 4B; +4.1 kJ/kgFFM/hr, p < 0.05, Figure 4C). Sim-
ilar differences were evident when activity data was used to cal-
culate REE, suggesting an increase in basal metabolic rate in
male Adr-Tg mice (in kJ/gBW/hr for WT, 42.0 ± 0.9; Adr-Tg,
45.3 ± 1.3; p < 0.05; in kJ/kgFFM/hr for WT, 55.8 ± 1.3; Adr-
Tg, 59.7 ± 1.9; p < 0.05). A difference of 4 kJ/day amounts to
180 kJ or approximately 5 g of fat over 6 weeks, which is compa-
rable to the actual difference in weight gain observed in Adr-Tg
mice relative to controls.
In contrast, female Adr-Tg mice had normal energy expendi-
ture (Figures 4A, 4B, and 4C) (REE in kJ/gBW/hr for WT, 35.5 ±
0.7; Adr-Tg, 34.8 ± 0.8; REE in kJ/kgFFM/hr for WT, 47.2 ± 1.1;
Adr-Tg, 46.0 ± 0.8). However, a significantly lower RQ during
the dark period in female Adr-Tg mice suggests altered substrate
metabolism (Figure 4D). Female Adr-Tg mice also exhibit in-
creased spontaneous locomotor activity during the dark period
(Figures 4E and 4F).
Food intake was not significantly different in chow-fed Adr-Tg
and WT mice, irrespective of gender (intake in kJ/day for male
WT, 60.1 ± 3.2; Adr-Tg 56.6 ± 1.5; for female WT 51.4 ± 4.6;
Adr-Tg 47.2 ± 1.8). Food intake of Adr-Tg was also not signifi-
cantly different when first exposed to HFD (intake in kJ/day for
male WT, 75.9 ± 2.5; Adr-Tg 74.2 ± 2.5; for female WT, 51.4 ±
4.6; Adr-Tg 47.2 ±1.8). Together, these observations indicate
that delayed DIO in Adr-Tg mice is primarily due to altered
metabolism, and does not involve significant suppression of
food intake.
The hypothalamus regulates energy expenditure and glucose
homeostasis through the autonomic nervous system (Morton
et al., 2006). To investigate the impact of adropin on the hypo-
thalamus, we measured serum leptin and brown adipose tissue
(BAT) uncoupling protein-1 (Ucp1) expression to determine
whether neuroendocrine function is altered in Adr-Tg. Serum
leptin levels in 6-month-old mice fed LFD or HFD exhibited the
predicted increase associated with DIO (p < 0.01) with no effect
of genotype (Figure 3I). The expression of Ucp1 in BAT was also
normal under HFD-fed or chow-fed conditions (expression in AU
in HFD-fed WT: 1.15 ± 0.08, HFD-fed Adr-Tg: 1.13 ± 0.13, p =
0.85; chow-fed WT: 1.11 ± 0.18, chow-fed Adr-Tg: 0.91 ± 0.10,
p = 0.33). Ucp1 expression is regulated by the sympathetic ner-
vous system and leptin (Cannon and Nedergaard, 2004). These
observations suggest that autonomic activity and leptin sensitiv-
ity are unlikely to be altered in Adr-Tg mice.
Attenuated Hepatic Steatosis in Adr-Tg Mice
Hepatic steatosis is frequently observed with obesity and insulin
resistance (Perlemuter et al., 2007). After 6 weeks on HFD, liver
TG content was significantly reduced in Adr-Tg mice compared
to control littermates (Figures 5A and 5B) associated with re-
duced expression of key enzymes involved in lipogenesis and
TG synthesis, stearoyl CoA desaturase 1 (Scd1), and fatty acid
synthase (Fas) (Figure 5C), with normal expression of genes in-
volved in fat oxidation (Figure 5C). Attenuated hepatic steatosis
of Adr-Tg mice may therefore result at least partially from re-
duced lipogenesis.
Adipose Tissue Lipogenic Gene Expression in Adr-Tg
As adipocytes also have a critical role in lipid homeostasis, we
examined expression of lipogenic genes in retroperitoneal
WAT. Expression of the Pparg gene, encoding a nuclear receptor
that regulates expression of genes involved in lipid synthesis
(Sharma and Staels, 2007), and a subset of Pparg-regulated
genes (Scd1, Fas, lipoprotein lipase [Lpl]) was significantly re-
duced in Adr-Tg mice compared to controls (Figure 5D). As ob-
served for liver, the expression of genes involved in fat oxidation
was not significantly different in WAT of Adr-Tg (Figure 5D). Over-
expression of adropin therefore affects the expression of genes
involved in lipogenesis in both liver and adipose tissue.
Adropin(34–76) Improves Glucose Homeostasis
Analysis of Adr-Tg mice suggests delayed obesity and a pre-
vention of the deterioration of glucose homeostasis associated
with weight gain. However, these studies did not determine
whether delivering adropin to obese, insulin-resistant mice
would rapidly reverse the deterioration of glucose homeosta-
sis. We therefore sought to establish whether treatment with
a synthetic form of adropin could improve glucose homeosta-
sis in DIO mice, using a synthetic peptide corresponding to the
secreted domain predicted by SignalP 3.0. Groups of individu-
ally housed 6-month-old male DIO mice were administered
adropin(34–76) at 0, 90, or 900 nmol/kg/day (n = 12 per dose)
by i.p. injection at 0900 hr and 1800 hr for 14 days. The groups
were matched for BW (41.5 ± 1.5, 41.8 ± 1.1, and 42.6 ± 1.0 g,
respectively). After 3 days of treatment, a reduction in food in-
take was observed in mice treated with 90 or 900 nmol/kg/
day of adropin(34–76) (Figure 6A), causing a modest but signif-
icant reduction of cumulative food intake over the treatment
period (Figure 6B). Weight loss coinciding with the reduction
in food intake after the third day of treatment was also evi-
dent, with BW stabilizing at 2.1–2.7 g (6%) below starting
weight after 9 days (Figure 6C). Adropin(34–76) treatment re-
duced hyperinsulinemia without affecting blood glucose (Fig-
ures 6D and 6E), increased serum adiponectin (Figure 6F), re-
versed hepatic steatosis (Figures 6G and 6H), and decreased
expression of hepatic expression of genes involved in TG
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Figure 3. Adr-Tg Mice Exhibit Attenuated Metabolic Distress Associated with Chronic Exposure to HFD
(A) Schematic showing the transgene construct with the adropin ORF ligated into a vector containing the human b-actin promoter.
(B) Representative RT-PCR analysis using transgene-specific primers; expression was observed in liver, heart, and whole brain.
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production and uptake (Figure 6I). However, while appearing
to be lower in the 900 nmol/kg/day group, the expression of
Pparg in WAT was not significantly different from controls
(Figure 6J).
The significant results observed with 2 weeks of treatment
demonstrate that a synthetic form of adropin is effective at re-
versing insulin resistance associated with obesity and chronic in-
take of a HFD. Moreover, these results were observed with the
lowest dose (90 nmol/kg) of a synthetic peptide not subject to
modifications that enhance the pharmokinetic profile.
Improvements in glucose homeostasis and hepatic steatosis
associated with 2 weeks of therapy could result from weight
loss. We therefore determined whether evidence for similar ef-
fects of adropin(34–76) on glucose homeostasis in DIO mice
would be observed with shorter treatment duration prior to sig-
nificant effects on BW. The dose of 90 nmol/kg/day required
several days to affect food intake and BW (Figures 6A, 6B,
and 6C). We therefore repeated a study using this dose with 2
days of bidaily injections (n = 8/group). As previously observed,
2 days of treatment did not significantly affect cumulative food
intake or BW (Figures 7A and 7B). However, there were signifi-
cantly lower fasting insulin and HOMA-IR values in the treatment
group, suggesting improved insulin sensitivity (Figure 7C). There
was no significant effect on fasting serum TG or leptin
(Figure 7C), suggesting that peptide treatment had not markedly
affected circulating lipids or leptin sensitivity. However, DIO
mice treated with adropin(34–76) for 2 days did have significantly
better glucose tolerance relative to controls (Figure 7D).
(C) Quantitative analysis of Enho mRNA in liver, muscle, and retroperitoneal WAT of WT and Adr-Tg mice (n = 3 per group, * p < 0.05).
(D) Western blot analysis of adropin IR in control HEK293 cells (no DNA), cells infected with adenovirus vector expressing adropin (Ad treated), and liver and
muscle tissue lysates from Adr-Tg (Tg) or WT mice.
(E) Body weight of WT and Adr-Tg mice fed HFD for 6 weeks (N = 3–8 for each genotype and sex). * p < 0.05 versus WT (within gender).
(F) Reduced FM and normal FFM for male mice shown in (E) after 6 weeks on HFD. *p < 0.05 for FM (n = 3 for WT, 8 for Adr-Tg).
(G) Blood chemistries for Adr-Tg mice fed HFD for 6 weeks. Transgenics exhibited reduced insulin, normal blood glucose, increased serum adiponectin (in
females), and reduced serum TG compared to WT mice.
(H–J) Improvements in glucose homeostasis in Adr-Tg mice are independent of reduced weight gain. Body weight and composition data from male Adr-Tg and
WT mice aged 6–7 months and maintained on chow or HFD are shown (60% kJ/fat) (H). Adr-Tg mice exhibited protection from hyperinsulinemia and hypergly-
cemia associated with obesity; reduced HOMA-IR values also suggested improved insulin sensitivity. Serum leptin levels were affected by diet (p < 0.01),
correlating with increased adiposity, but not by genotype (I). Glucose clearance was also significantly improved in Adr-Tg mice relative to controls, irrespective
of diet (J). All data are mean ± SEM.
Figure 4. Analysis of Whole Body Energy Metabolism in Chow-Fed Adr-Tg and WT Mice
(A) Total 24 hr energy expenditure (TEE) of male and female Adr-Tg mice compared to controls.
(B and C) TEE expressed per g body weight (B) or FFM (C) (*p < 0.05).
(D) RQ of male and female Adr-Tg and WT mice (*p < 0.05).
(E and F) Spontaneous locomotory activity of female Adr-Tg and WT mice (*p < 0.05). In (E), the data are presented as mean X beam breaks over 24 hr, during the
lights-on period (0600-1800 hr; L or white bar) and during the dark period (1800-0600 hr; D or black bar), by gender. All data are mean ± SEM and are the mean
from 3 days of recordings; n = 7–8 each genotype and sex.
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A second study examined the effects of a wider dose range
(0–9000 nmol/kg/day, n = 6/group) administered for 2 days on
liver metabolism. Again, no significant difference in BW pre- or
postinjection was observed, even with the highest dose of
9000 nmol/kg/day (Figure 7E). Evidence for improvements in glu-
cose homeostasis was again observed, with a significant reduc-
tion in glucose and HOMA-IR observed with the 900 nmol/kg
dose (Figures 7F and 7H). While serum insulin levels were lower,
the effect did not achieve statistical significance in this study
(Figure 7G). Liver TG content was also not affected after
2 days of treatment (Figure 7I). However, the expression of genes
involved in fatty acid metabolism was significantly different in the
treatment groups, with reductions in the expression of Sreb1c,
Scd1, and Dgat2 mRNA (Figure 7J).
Together, these observations show that improvements in glu-
cose homeostasis and hepatic lipid metabolism associated with
with adropin(34–76) therapy occur rapidly and are independent of
reduced BW or altered food intake.
DISCUSSION
Our studies have identified a gene encoding a secreted peptide
involved in energy homeostasis. Hepatic expression of the Enho
transcript is altered with obesity and changes in energy status
and in response to dietary macronutrients, which initially sug-
gested that it was associated with energy homeostasis. The
Enho gene encoding adropin is also expressed in areas of the
brain involved in metabolic regulation. We demonstrated the ef-
fects of adropin on energy homeostasis using transgenic overex-
pression of the ORF and by systemic treatment using a synthetic
peptide. These therapies significantly affected weight gain and
improved glucose homeostasis. Adropin also affected glucose
homeostasis and lipid metabolism independently of weight
loss. Adropin thus appears to have a significant role in energy
homeostasis, and may be involved in the metabolic adaptation
to fasting and dietary macronutrients. Adropin may thus provide
an important new lead for the development of therapies to im-
prove glucose homeostasis.
Impaired function of peptide factors that regulate energy ho-
meostasis contributes to a deterioration of glucose and lipid ho-
meostasis associated with obesity, with leptin and adiponectin
secreted by adipocytes being well-investigated examples (Flier,
2004; Scherer, 2006). Our results suggest that deregulation of
adropin production may also be a factor linking obesity with
steatosis and insulin resistance. The effects of adropin replace-
ment therapy observed in DIO mice are consistent with a signifi-
cant role for this peptide in maintaining glucose homeostasis.
However, confirmation that a decline in adropin is a major factor
Figure 5. Attenuated Hepatic Steatosis and Altered Expression of Genes Involved in Lipid Metabolism in Adr-Tg Mice
(A) Hematoxylin- and eosin-stained liver sections showing less severe macrovesicular fatty change in livers of Adr-Tg mice compared to WT.
(B) Liver TG content is lower in Adr-Tg mice (n = 3–8 each genotype and sex, *p < 0.05 versus WT).
(C) Expression of stearoyl-CoA desaturase-1 (Scd1), fatty acid synthase (Fas), and lipoprotein lipase (lpl) mRNA is reduced in liver of male and female Adr-Tg mice
compared to WT (n = 3–8 each genotype and sex, *p < 0.05 versus WT). Liver data shown in (A)–(C) was from mice fed HFD for 3 months.
(D) Expression of genes involved in fatty acid metabolism in WAT from male and female Adr-Tg and WT mice. * p < 0.05. Values shown are mean ± SEM from mice
fed HFD for 6 weeks.
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in the deterioration of glucose and lipid metabolism in the obese
state will require investigating adropin deficiency due to targeted
gene deletion.
The observation that hepatic Enho expression correlates with
dietary fat intake and regulation by LXR agonists suggests a role
in adapting substrate metabolism to macronutrient intake. The
efficient coordination of substrate oxidation with fat and carbo-
hydrate content of the diet is an important feature of energy ho-
meostasis. Individuals with a family history of type 2 diabetes ex-
hibit impaired metabolic flexibility and do not efficiently match fat
oxidation with consumption (Heilbronn et al., 2007). Impaired co-
ordination of substrate oxidation with dietary macronutrient con-
tent is also a factor in obesity of mice and humans with MC4R
mutations (Butler, 2006; Nogueiras et al., 2007). The observation
that hepatic Enho expression is regulated by dietary fats and
LXRa suggests a role in adapting substrate metabolism to mac-
ronutrient intake. If the hypothesis that adropin acts as a meta-
bolic signal to adapt substrate metabolism with fat intake is cor-
rect, then a decline in adropin synthesis with obesity may be
a factor in the impaired ability to match lipid metabolism with di-
etary fat intake, promoting steatosis, dyslipidemia, and glucose
intolerance.
In mice, transition from low- to high-fat diets is associated with
a rapid shift in substrate metabolism to increase fat oxidation
and reduce lipogenesis (Butler, 2006; Sampath and Ntambi,
2005). This response involves nuclear receptors that act as lipid
and glucose sensors and that subsequently act to regulate the
expression of clusters of genes expressing key metabolic en-
zymes (Kalaany and Mangelsdorf, 2006; Sampath and Ntambi,
2005; Uyeda and Repa, 2006). The regulation of Enho transcrip-
tion by macronutrients observed in the current study could
involve intracellular sensors of carbohydrates and fatty acids.
In the current study, we observed that LXRa agonists rapidly
reduced the expression of Enho mRNA in cultured HepG2
cells and in liver of live mice. LXRs stimulate lipogenesis in
liver and promote storage of energy as TG in adipose tissue
(Kalaany and Mangelsdorf, 2006). As adropin therapy is associ-
ated with suppression of lipogenic gene expression and reduces
Figure 6. Adropin(34–76) Therapy Affects Energy Metabolism in DIO B6 Mice and Cultured Adipocytes
(A–J) Administration of adropin(34–76) by i.p. injection at 0900 and 1800 hr for 14 days is associated with reduced food intake (A and B) and weight loss (C). Adropin
treatment reduced fasting insulin (D) without affecting blood glucose (E), and increased serum adiponectin (F), suggesting improved insulin sensitivity. Adropin
treatment improves hepatic steatosis (G) and significantly reduces liver TG accumulation (H), associated with reduced expression of genes involved in lipid syn-
thesis in liver (I). Pparg expression in WAT of mice treated with adropin(34–76) was not significantly different from controls treated with saline (J). The values shown
are mean ± SEM with N = 12/treatment group.
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adiposity, suppression of adropin synthesis by LXRa may facili-
tate the effects of LXRs to promote synthesis and storage of TG.
Both LXRa and LXRb have recently been suggested to act as
glucose sensors (Mitro et al., 2007), although these data are con-
troversial (Denechaud et al., 2008). We have shown that the stim-
ulation of LXRa suppresses hepatic Enho expression. Therefore,
stimulation of LXR by diets with a high carbohydrate intake may
provide a hypothesis for explaining the regulation of liver Enho
expression by dietary macronutrients. However, at this time,
the mechanisms by which the macronutrient content of the
diet regulates liver Enho expression remain unclear. A simple
model involving stimulation of liver Enho transcription by the
other known regulators of lipid metabolism in liver such as Ppara,
Srebp1, and ChREBP is unlikely. The activity of these transcrip-
tion factors is stimulated when Enho expression is low, such as
after fasting (Ppara) (Reitman, 2007) and consumption of high-
carbohydrate, low-fat diets (Srebp1, ChREBP) (Horton et al.,
2002; Uyeda and Repa, 2006).
Several observations suggest that adropin may have a role in
the regulation of lipogenesis. Adropin therapy rapidly reduces
the expression of genes involved in lipogenesis in liver. Trans-
genic mice overexpressing adropin (Adr-Tg) mice exhibit lower
expression of genes involved in lipogenesis in liver and adipose
tissue. A lower RQ observed in female Adr-Tg mice also sug-
gests altered substrate metabolism. While these effects on liver
gene expression could be due to weight loss and improvements
in insulin sensitivity, suppression of liver lipogenic genes was
also observed prior to significant effects on food intake or weight
Figure 7. Short-Term Treatment with Synthetic Adropin(34–76) Improves Glucose Homeostasis in DIO B6 Mice Independently of Weight Loss
or Reduced Food Intake
(A–D) Treatment of male DIO mice with 90 nmol/kg/day adropin(34–76) administered as two i.p. injections/day over 2 days did not significantly affect food intake (A)
or weight gain (B) (n = 8/group). Treatment followed a 5 day lead-in period, with the injection period marked by the gray area. Following treatment, there were
significant improvements in glucose homeostasis, indicated by reductions in fasting insulin and HOMA-IR values (C) and improved glucose tolerance (D).
* p < 0.05 compared to saline. However, there were no changes observed in serum TG (C).
(E–J) A second study assessed a dose-response to 2 days of injections on glucose homeostasis (F–H) and liver metabolism (I, J) (n = 6/group). There was no
significant effect of treatment on body weight (E, the white and solid bars are body weight pre- and posttreatment). There was evidence for improved glucose
homeostasis (F–H), with significant reductions in fasting glucose (F) and HOMA-IR (H). While liver TG content was not significantly affected by treatment (I), there
were changes in the expression of genes involved in fatty acid metabolism, which was statistically significant for Scd1 and diacylglycerol O-transferase 2 (Dgat2)
(J). * p < 0.05 versus saline. The values shown are mean ± SEM.
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loss. In the fed state, liver Enho expression also correlates neg-
atively with lipogenic activity, with lower expression observed
during refeeding with high-carbohydrate diets and increased ex-
pression on diets with high fat and low carbohydrate content.
However, liver Enho expression also declines with fasting, which
is a state of minimal lipogenesis. In this situation, the loss of an
inhibitory signal may not dominate other endocrine and neural
inputs that regulate carbohydrate and lipid metabolism (Reit-
man, 2007). However, it is also possible that a decline in adropin
production may provide a regulatory signal involved in the
homeostatic metabolic adaptation to fasting, analogous to the
instigation of metabolic adaptations to fasting that are associ-
ated with a decline in serum leptin (Morton et al., 2006).
Adr-Tg mice exhibited normal leptin and expression of Ucp1 in
BAT, suggesting that adropin does not affect energy metabolism
through altered leptin sensitivity or BAT thermogenesis. It is likely
that adropin regulates energy homeostasis through other mech-
anisms that include suppressing lipogenesis. Female Adr-Tg
mice also exhibited a significant increase in physical activity,
which may be a mechanism for regulating whole body substrate
metabolism. While activity of male Adr-Tg mice was not signifi-
cantly different, there was evidence for a modest increase in
energy expenditure when adjusted for body mass. While specu-
lative, the increase in serum adiponectin associated with adropin
treatment may also stimulate oxidative metabolism (Scherer,
2006).
While adropin(34–76) treatment reduced food intake in DIO B6
mice, this response was only evident after 3 days of treatment.
This may suggest an indirect mechanism secondary to improve-
ments in lipid metabolism and insulin sensitivity. However, Enho
is expressed in the brain, including the area postrema and dorsal
vagal complex, which are involved in regulating ingestive behav-
iors. It is also worth noting that Enho mRNA is expressed in other
areas of the central nervous system involved in relaying sensory
information (brainstem), regulating complex behaviors (thala-
mus), temperature regulation (periaqueductal gray), and circa-
dian rhythms (lateral geniculate nucleus and medial habenula).
Whether adropin functions as a neuropeptide in the central ner-
vous system to affect homeostatic regulation of metabolism
remains to be investigated.
In summary, adropin is a newly discovered secreted peptide
that is involved in energy homeostasis and lipid metabolism.
Expression of Enho and secretion of adropin by the liver is
proposed to be involved in peripheral lipid homeostasis in re-
sponse to variable macronutrient consumption. This could in-
volve both paracrine effects on hepatocyes or actions as an en-
docrine signal of macronutrient consumption and energy status.
Adropin may form the basis for the development of new thera-
peutic targets for treating metabolic disorders associated with
obesity.
EXPERIMENTAL PROCEDURES
Animal procedures complied with NIH guidelines and were approved by the
Pennington Biomedical Research Center or Columbia University Institutional
Animal Care and Use Committee.
Animals
Melanocortin receptor knockout mice have been previously described
(Sutton et al., 2006). Lean and DIO B6 (60% kJ HFD from 6 through 26 weeks),
Lepob/Lepob, and Ay/a mice were purchased from the Jackson Laboratory (Bar
Harbor, MN). Mice were housed in a 12 hr light/dark period (lights on: 0600-
1800 hr). Low-fat (10% kJ/fat, D12450B) or high-fat (60% kJ/fat, D12492) diets
were purchased from Research Diets, Inc. (New Brunswick, NJ). For CR,
8-week-old Ay/a mice were fed 70% of their prior measured daily ad libitum
intake for 16 weeks. FM and FFM were estimated using nuclear magnetic res-
onance (Bruker Mice Minispec NMR Analyzer; Bruker Optics, Inc.; Billerica,
MA) and validated against dual X-ray absorptiometry and standard chemical
composition analysis (Tinsley et al., 2004). For i.v. administration of the LXRa
agonist, GW3965 (10 mg/kg) was administered into the tail vein of B6 mice
(aged 12 weeks, BW of 25 g); liver was collected for RNA extraction 4 hr after
the injection.
Expression Vectors
The adropin ORF was amplified from mouse liver cDNA using primers with
Not1 (50-ggggcggccgcaccatgggggcagccatctcccaa-30) and Xho1 (50-gggctcga
gggccagagcccttcagggctgcag-30) restriction enzyme sites and ligated into
p3 3 FLAG-CMV-14 Expression Vector (Sigma-Aldrich; St. Louis, MO).
Constructs expressing the native form, or with a C-terminal FLAG epitope,
were verified by sequencing. Expression of the native and FLAG-tagged
protein was confirmed in transiently transfected HEK293 cells (Lipofectamine
2000; Invitrogen) using both an anti-FLAG antibody and a polyclonal anti-
body raised against adropin (Sigma-Genosys; The Woodlands, TX). The
DNA encoding the native or FLAG-tagged forms was ligated into the BstXI
and Xba1 sites of pAd5-Blue and recombinant adenovirus generated using
previously described methods (Moraes et al., 2001). Viral particles were
purified using a Vivapure AdenoPACK 100 (Vivascience AG; Hannover,
Germany). Mice were administered 100 ml of 5 3 108–9 pfu of virus into the
tail vein.
Adropin-Transgenic Mice
The adropin ORF was subcloned into a human b-actin promoter vector. After
excision from vector sequences, transgenic animals were generated by pronu-
clear injection into B6 fertilized eggs.
Energy Expenditure
Physical activity and energy expenditure were measured using a 16-chamber
Comprehensive Laboratory Animal Monitoring System (Columbus Instru-
ments; Columbus, OH) (Butler, 2006). Spontaneous physical activity was mea-
sured using an OPTO-M3 sensor system. REE was calculated using measure-
ment made when X movements averaged < 0.5 beam breaks/hr.
Adropin(34–76) Treatment Study
Synthetic adropin(34–76) was provided by Biomeasure, Inc./IPSEN (Milford,
MA). Peptide was synthesized using standard Fluorenylmethyloxycarbonyl
(Fmoc) chemistry on PEG resin. In each deprotection step, the Fmoc group
was removed by treatment with 20% piperidine in N,N-dimethylformamide
(DMF) for 30 min. The resin was washed with DMF. In each coupling step,
five equivalents of Fmoc amino acid, five equivalents of 2-(1-H-benzotria-
zole-1-yl)-1,1,2,3-tetramethyluronium hexafluorophosphate (HBTU), and one
equivalent of diisopropylethylamine (DIEA) in DMF were used. The coupling
time was 1 hr. At the end of the peptide chain assembly, the peptide was
cleaved off from the resin using trifluoroacetic acid (TFA) containing 5% phe-
nol, 2% ethanedithiol, and 2% anisol. The crude linear peptide was precipi-
tated with ether, cyclized in aqueous solution containing 10% dimethyl sulfox-
ide (DMSO, pH 8.5), and purified by reverse-phase high-pressure liquid
chromatography (HPLC). The final product was analyzed by amino acid anal-
ysis, analytical HPLC, and mass spectrometry.
For treatment, adropin(34–76) suspended in 0.9% saline with 0.1% bovine se-
rum albumin was administered by i.p. injection at 0800 and 1800 hr. The doses
used were based on prior experience testing novel secreted peptides. DIO B6
mice were acclimated for 10 days to stainless steel wire-bottomed cages; food
intake was measured by weighing food in the hopper and correcting for spill-
age. After the final injection, mice were fasted overnight and euthanized at
1100 hr. Trunk blood was collected, and tissue samples (liver and retroperito-
neal WAT) were frozen in liquid N2. A portion of the liver from three animals per
group was fixed with formalin and processed by Pathology Laboratory, LSU
School of Veterinary Medicine.
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Microarray Analysis
Microarrays were performed by the Genomics Core Facility of the Pennington
Biomedical Research Center using total RNA isolated from lean and obese
Mc3rKO and age-matched littermates as described previously (Koza et al.,
2006). Validation of gene expression involved was performed in either 96- or
384-well plates with TaqMan Universal PCR Master Mix or SYBR Green
PCR Master Mix (Applied Biosystems; Foster City, CA) and an ABI PRISM
7900HT Sequence Detection System (Applied Biosystems), as previously
described (Koza et al., 2006).
Quantitative RT-PCR and Northern Blot
Total RNA was extracted using either TRI reagent or TRIzol (Invitrogen; Carls-
bad, CA) and reverse transcribed using Superscript III Reverse Transcription
System (Invitrogen; Carlsbad, CA). Analysis of gene expression with cyclophi-
lin B as reference was performed in 384-well plates, using TaqMan Universal
PCR Master Mix or SYBR Green PCR Master Mix and an ABI PRISM
7900HT Sequence Detection System. Sequences of oligonucleotide primers
and probe (Integrated DNA Technologies; Coralville, IA) for Enho were de-
signed using Primer Express 2.0 (Applied Biosystems): forward 50-atggcctcgta
ggcttcttg-30, reverse 50-ggcaggcccagcagaga-30, probe 50-FAM-tgctactgctctg
ggtc-BHQ-30. Sequences of primer-probe combinations for other genes were
designed and validated as reported previously (Sutton et al., 2006).
For northern analysis, a 210 bp DNA probe corresponding to Enho coding
sequence was labeled with 32P-dATP (>3000 Ci/mmol) using Prime-It II Ran-
dom Primer Labeling Kit (Stratagene; La Jolla, CA). (1 3 106)–(1 3 107) cpm
of denatured probe was hybridized with a Multiple Tissue Northern Human
RNA Blot (BD Biosciences Clontech; Palo Alto, CA). For analysis of gene
expression in mice, total RNA was extracted from tissues or differentiated
3T3-L1 adipocytes as previously described (Floyd and Stephens, 2002). Blots
were exposed to a phosphor screen and images captured using a Molecular
Dynamics Phosphorimager (Sunnyvale, CA).
Generation of Enho cRNA Probe and In Situ Hybridization
Histochemistry
cDNA obtained from mouse brain was used as a template to amplify three
sequences by PCR: a 401 bp sequence corresponding to nt 98–498 of the
Enho transcript (primers: 50-CTGAATTCGACAGGACAGCCACCTTGGAT-30
and 50-AGAAGCTTCGATTCCACGCTCTGACTCAG-30); a 524 bp sequence
corresponding to nt 38–561 (primers: 50-CTGAATTCTCAACTCAGGCCCAGG
ACTG-30 and 50-AGAAGCTTAATCTAGGCTGCTGGGTCCA-30 ); and a 234 bp
sequence corresponding to nt 205–438, which contains coding sequence
only (primers: 50-CTGAATTCATGGGGGCAGCCATCTCCCA-30 and 50-AGA
AGCTTTCAGGGCTGCAGCAGGTAGC-30). The respective amplification prod-
ucts were ligated into the pcDNA3 vector (Invitrogen; Paisley, UK); inserts were
verified by DNA sequencing. Plasmids linearized by digestion with EcoRI were
used to generate antisense 35S-labeled cRNA using T7 RNA polymerase (Am-
bion). Sense probes were also generated by linearizing plasmids with HindIII
and using SP6 RNA polymerase (Ambion).
Eight-week-old male B6 mice were anesthetized with pentobarbital
(50 mg/kg i.p.) and then perfused transcardially with diethylpyrocarbonate
(DEPC)-treated phosphate buffered saline (PBS) followed by 10% neutral buff-
ered formalin. After postfixing in the same fixative for 4 hr at 4C, brains were
then immersed in 20% sucrose in DEPC-treated PBS at 4C overnight and cut
coronally at 25 mm on a freezing microtome. Tissue sections were mounted
onto SuperFrost slides (Fisher Scientific; Loughborough, UK) and air dried.
Sections were fixed in 4% formaldehyde in DEPC-treated PBS for 20 min at
4C, dehydrated in ascending concentrations of ethanol, cleared in xylene
for 15 min, rehydrated in descending concentrations of ethanol, and placed
in prewarmed sodium citrate buffer (95–100C, pH 6.0). Slides were placed
in an LG Intellowave commercial microwave oven (Slough, UK) for 10 min at
95–100C, dehydrated in ascending concentrations of ethanol, and air dried.
In situ hybridization was performed as previously described (Heisler et al.,
2006). Briefly, 35S-labeled Enho cRNA probes diluted to 106 cpm/ml in hybrid-
ization solution and coverslips were applied to mounted sections, which were
incubated for 16 hr at 57C. Sections were incubated in 0.002% RNase A
(QIAGEN; Crawley, UK) for 30 min and then sequentially washed in decreasing
concentrations of SSC. Sections were dehydrated in graded ethanol
containing 0.3 M NH4OAc followed by 100% ethanol. Slides were air dried
and placed in X-ray film cassettes with BMR-2 film (Kodak; Rochester, NY)
for 3 days.
Cell Culture
Culture and treatment of HepG2 cells with LXR and FXR agonists, and
inhibition of LXRa using siRNA, were described previously (Stayrook et al.,
2008; Wang et al., 2008). LXR and FXR agonists are from Sigma-Aldrich
(St. Louis, MO).
Western Blot
Lysates or conditioned media were homogenized on ice in lysis buffer (Cell
Signaling; Beverly, MA) and centrifuged, and aliquots diluted with 23 electro-
phoresis buffer (50 mM Tris HCl, pH 6.7, 4% w/v glycerol, 4% SDS, 1%
2-mercptoethanol, and 0.02 mg/ml bromophenol blue). Ten micrograms pro-
tein was separated on a 4%–20% SDS-polyacrylamide gradient gel (BioRad;
Hercules, CA), transferred to Immobilon-P polyvinylidene diflouride mem-
branes in Towbin-transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol,
and 0.01% SDS), and then incubated with antibodies. Membranes were
washed five times in PBST and incubated with horseradish peroxidase-conju-
gated goat anti-rabbit immunoglobulin. Membranes were then washed as
above and the antigen-antibody-peroxidase complex detected by enhanced
chemiluminescence (Amersham Biosciences; Piscataway, NJ).
A polyclonal antibody was generated using 14 amino acid antigen corre-
sponding to amino acids 37–50 of adropin, which was used to elicit an antisera
response in two New Zealand white rabbits (Sigma-Genosys). The third pro-
duction bleed from one rabbit was affinity purified (Sigma-Genosys) and
used for western blot analysis.
Serum Measurements, Glucose Tolerance Tests,
and Determination of Hepatic Lipid Content
Blood glucose was measured using a Glucometer Elite XL (Bayer Corporation;
Elkhart, IN). Plasma lipids were measured on a Beckman Synchron CX7 for ter-
minal experiments or commercially available kits (Wako Diagnostics; Rich-
mond, VA). For glucose tolerance tests, mice were fasted overnight and blood
samples taken at time 0 (baseline) or 15–60 min after an i.p. injection of glucose
(1 mg/kg). Hepatic TG content was measured as previously described (Sutton
et al., 2006). Serum insulin was measured using a commercially available kit
(Crystal Chem; Downer’s Grove, IL). HOMA-IR was calculated as follows: (fast-
ing insulin [mU/ml] 3 fasting glucose [mmol/l]) / 22.5.
Statistics
All data presented are mean ± SEM. JMP IN 5.1 (SAS Institute, Inc.; Cary, NC)
was used for statistical analysis; two or multiple groups of data used either Stu-
dent’s t test or one-way and two-way ANOVA. Significance was assumed for
P values < 0.05.
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